Blubber oil

Other Names

cold-pressed whale oilmarine mammal oilmisirakseal blubber oilseal oiltrain oiluqhuquqsuqwhale oil

Synopsis

Blubber Oil

1. Identity: Names, Sources, and Forms

Nomenclature

Blubber oil is the rendered lipid fraction extracted from the blubber—the thick subcutaneous adipose layer—of marine mammals, principally seals (most commonly the harp seal, Pagophilus groenlandicus), whales (including bowhead, right, and sperm whales), and walruses. In the dietary supplement trade it is most frequently encountered as seal oil, though the broader term "blubber oil" encompasses all marine-mammal-derived oils of this type. Historically, oil rendered from whale blubber was called whale oil or train oil—the latter term derived from the Dutch traan, meaning "teardrop," reflecting the oil's droplet-like extraction during processing or its clear, teardrop appearance post-refining. "Train oil" was the standard European commercial designation from the sixteenth century onward. Whale oil has low viscosity (lower than olive oil), is clear, and varies in color from a bright honey yellow to a dark brown, according to the condition of the blubber from which it has been extracted and the refinement through which it went.

Natural Source and Structure of Blubber

Blubber is a special adaptation of the skin of marine mammals that has multiple functions related to energy storage, buoyancy, thermal insulation, and streamlining. The blubber may vary in thickness depending on a number of variables, but is on average about 5 cm thick for seals. Studies of the ringed seal (Pusa hispida) have revealed that the blubber column is chemically stratified: analysis of 58 fatty acids sampled at 3-mm intervals throughout the blubber column revealed three chemically distinct layers, with the average depths of the outer and inner layers being approximately 1.5 cm and 1 cm, respectively. Monounsaturated fatty acids (MUFAs) are more abundant in the outer layer while saturated fatty acids are in greater proportion in the inner layer, suggesting that inner and outer blubber layers have different functions—the inner layer playing a diet-related role and the outer layer a more functional and structural role.

Common Commercial Forms

Seal blubber oil is a by-product of seal meat and seal industries. In the commercial supplement market, blubber oil (sold as seal oil) is available as soft-gel capsules (including enteric-coated formulations), liquid oils, and emulsions. Products providing 100–5,000 milligrams of EPA, DHA, and DPA per day are regulated under Health Canada's Natural Health Products framework; the finished product specifications must be established in accordance with the Natural and Non-prescription Health Products Directorate (NNHPD) Quality of Natural Health Products Guide, and the medicinal ingredient must comply with the requirements outlined in the NHPID. Although delayed-release dosage forms are usually not supported by standard monographs, the Health Canada seal oil monograph includes 'Capsule, soft, enteric-coated,' which is commonly used for marine oil products.

2. Traditional and Historical Use

Indigenous Arctic and Sub-Arctic Peoples

Whaling and sealing have been traditional activities among indigenous communities all over the world for thousands of years; they are still practised by some of these small communities today, and can provide food, tools and even a sense of purpose and discipline. Norwegians were among the first to hunt whales, as early as 4,000 years ago; the Japanese may have been doing so even earlier. Traditions as varied as the Inuit (who hunted in the Arctic Ocean), Basque (who hunted in the Atlantic), and Japanese (who hunted in the Pacific) relied on whales to provide material goods as well as part of their cultural identity.

For Inuit peoples across the Arctic, blubber oil was a dietary staple and a multi-purpose resource. Nearly every part of the whale was used; meat, skin, blubber, and organs were eaten as an important source of protein, fats, vitamins, and minerals. The blubber of the beluga was often rendered into oil for cooking and lamp fuel; rendered oil (misirak) must be anaerobically fermented—meaning fermented without the presence of oxygen—and it continues to be a highly prized Inuit delicacy, eaten as a condiment with dried, frozen or cooked meats. Some 300 litres of oil can be produced from the blubber of one beluga.

The rendered blubber oil served as the primary fuel for the qulliq, the traditional stone lamp used across the circumpolar world. The qulliq (Inuktitut: ᖁᓪᓕᖅ) is the traditional oil lamp used by many circumpolar peoples, including the Inuit, the Chukchi, and the Yupik peoples; the fuel is seal oil or blubber, and the lamp is made of soapstone. This lamp provided warmth and light in the harsh Arctic environment where there was no wood, and where the sparse inhabitants relied almost entirely on seal oil or whale blubber as fuel; it was the single most important article of furniture for Inuit in their dwellings. Groups such as the Inuit of North America are granted special whaling rights, integral to their culture, and they still use whale oil as a food and as lamp oil in the ceremonial qulliq.

The nutritional importance of blubber and its rendered oil to Arctic populations extended to vitamin provision. Beluga skin and blubber contain zinc, retinol, and other essential nutrients, but are especially rich in vitamin C, which is why Inuit traditionally never suffered from scurvy. Intake of EPA and DHA in Greenland Inuit was notably high—at least 4.5–10.5% of total fatty acids in the 1970s—because of their reliance on whale, seal, and fish meat.

European Commercial and Industrial Use

During the Middle Ages and Renaissance, whaling gained popularity throughout Northern Europe; whale oil and baleen were valuable commodities. Whale oil, from the blubber of right and bowhead whales and the head cavity of sperm whales, was used to make candles and for oil lamps; it is also a source of fat and has been used to make soap and butter or margarine. From the late eighteenth century, whale oil was increasingly used to lubricate machinery and, during periods of conflict, could be used to lubricate rifles and other military instruments.

The industrialized commercial whaling boom of the eighteenth and nineteenth centuries greatly expanded these uses. Whale oil was widely used in the First World War as a preventive measure against trench foot; an infantry battalion of the British Army during World War I on the Western Front could be expected to use 10 imperial gallons (45 L) of whale oil a day, rubbed directly onto bare feet in order to protect them from the effects of immersion.

The whaling industry dwindled as petroleum and natural gas replaced whale oil as a major fuel source. Vegetable oils replaced whale oil in margarine and soaps. In the twenty-first century, with most countries having banned whaling, the sale and use of whale oil has practically ceased. Seal oil, however, continues to be harvested commercially and sold as a dietary supplement, most notably in Canada, where it is regulated under the Natural Health Products Regulations.

3. Key Constituents and Active Compounds

Lipid Class Composition

The oils from marine mammals contain various lipid classes, including triacylglycerols, diacylglycerols, monoacylglycerols, free fatty acids, wax esters, cholesterol, cholesterol esters, hydrocarbons, vitamins, and ether lipids. Triacylglycerols (TAG) of seal blubber oils are the main component of neutral lipids, which contain a variety of lipid classes; neutral lipids account for 98.9% of blubber in contrast to intramuscular lipids (78.8% neutral and 21.1% polar lipids).

Whale blubber has a notably different lipid class profile from that of seals. Whale oils are especially interesting because some contain fatty acids largely in the form of wax esters; the oils from the blubber of the Physeteridae may consist mainly of wax esters, and sperm whale blubber oil consists of a mixture of about 79% wax esters and 21% TAG. The blubber fat of beaked whales (Berardius, Hyperoodon, and Ziphius) is composed almost entirely of wax esters (94–99%) along with low levels of TAG (2–6%).

Omega-3 Fatty Acids: EPA, DHA, and DPA

The principal nutritionally active compounds in blubber oil are long-chain polyunsaturated omega-3 fatty acids (LC n-3 PUFAs). Both blubber oil and muscle oil contain high proportions of 20:5 and 22:6 fatty acids, a characteristic of marine oils. These correspond to eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3).

A key compositional distinction between seal-derived blubber oil and most fish oils is the presence of a third long-chain omega-3: docosapentaenoic acid (DPA; 22:5n-3). Seal oil contains DPA at approximately 5% by weight of the total seal oil, at levels generally higher than almost all fish oils. Seal meat and human breast milk are rich in n-3 DPA. Docosapentaenoic acid (DPA) designates any straight open-chain polyunsaturated fatty acid (PUFA) containing 22 carbons and 5 double bonds; DPA is primarily used to designate two isomers, including all-cis-7,10,13,16,19-docosapentaenoic acid (the n-3 form).

The best dietary source of EPA and DHA (and also docosapentaenoic acid) is seafood, especially fatty fish; the blubber and tissues of sea mammals, such as whales and seals, also contain EPA and DHA in significant amounts.

Stereospecific Position of Fatty Acids

A biochemically significant feature of seal blubber oil concerns the positional distribution of fatty acids on the glycerol backbone of its triacylglycerols. In marine mammals, eicosapentaenoic acid (EPA; 20:5 n-3) and docosahexaenoic acid (DHA; 22:6 n-3) are found mainly at the sn-1 and sn-3 positions of TAG, whereas in fish these fatty acids are positioned in sn-2. The distribution of fatty acids in seal oil differs from that of fish oil; chemical analysis of the structure of seal oil shows that EPA, DHA, and DPA are mainly distributed in the first and third positions, compared to fish where they are mainly in the second position. Seals, like humans, are mammals; therefore, seal oil triglycerides have the same first-and-third distribution of fatty acids as human triglycerides. The functional significance of this sn-positional difference for human absorption and metabolism has been proposed in the research literature as a potential differentiating factor, though its clinical magnitude has not been definitively established.

Sperm Whale Blubber Oil: Fatty Acid Profile

The fatty acid profiles of triacylglycerols and wax esters in sperm whale blubber are broadly similar in overall composition, being predominantly high in MUFAs (~74–80%) and low in PUFAs (~2–5%), with saturated fatty acids contributing about ~16–19%. This composition differs substantially from seal blubber, which has proportionally higher PUFA content.

Other Constituents

In addition to TAG, wax esters (long-chain alcohols esterified to fatty acids) are another important group of neutral lipids found in marine mammals; most species of marine mammals have C32, C34, C36, and C38 (total of alcohol plus acid) as major components. Blubber oil also contains fat-soluble vitamins, particularly vitamins A and D, which were historically significant for nutrition in vitamin-limited Arctic environments.

4. Mechanisms of Action

Omega-3 Fatty Acid Mechanisms

Omega-3 fatty acids, such as EPA and DHA, may reduce the risk of atherosclerotic cardiovascular disease (ASCVD) events through various mechanisms, including triglyceride lowering, membrane stabilization, and antithrombotic, anti-inflammatory, or antiarrhythmic properties.

The cardioprotective effect of EPA and DHA is most likely due to the beneficial modulation of a number of known risk factors for CVD, such as blood lipids, blood pressure, heart rate and heart rate variability, platelet aggregation, endothelial function, and inflammation. More specifically, omega-3 is able to improve cardiovascular health by modulating different pathways linked to blood pressure control, glycemic metabolism, increase in expression and synthesis of lipoprotein lipase (and consequent reduction of triglycerides), improvement in lipid metabolism, decrease in LDL-C and increase in HDL-C, and decrease of very low-density lipoprotein (VLDL).

Role of DPA

DPA (22:5n-3) has been described as a metabolic intermediary and potentiator. Research published in Progress in Lipid Research (Kaur et al., 2011; PMID 20655949) examined its biological effects. Suggested modes of action for marine n-3 PUFAs include their modulation of eicosanoid synthesis and reduction in plasma triglyceride concentration. In vitro evidence from Kanayasu-Toyoda et al. (1996) demonstrated that DPA is a potent stimulator of endothelial cell migration, a function critical for blood vessel repair, at lower concentrations than EPA.

Role of sn-Position in Absorption

The fat composition of seal oils differs significantly from that of fish; in marine mammals, EPA and DHA are found mainly at the sn-1 and sn-3 positions of TAG, whereas in fish these fatty acids are positioned in sn-2, which may display different effects on conditions such as NAFLD associated with hyperlipidemia than fish oils. The pancreatic lipase-mediated hydrolysis of dietary triglycerides preferentially cleaves fatty acids at the sn-1 and sn-3 positions, releasing them as free fatty acids for direct absorption; this structural difference is mechanistically relevant but has not yet been fully validated in large comparative clinical trials.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular Health and Lipid Profile

Systematic Reviews and Meta-Analyses (Seal Oil Specific)

Seal oil (SO) supplementation has been purported to have cardiovascular health benefits due to its content of omega-3 fatty acids; however, the clinical evidence base for this intervention had not been comprehensively assessed until a 2025 systematic review and meta-analysis aimed to evaluate the effects of oral SO supplementation on lipid profile biomarkers. Nine RCTs were included in the review after screening of 242 studies, comprising a total of 626 patients. Supplementation of SO resulted in no statistically significant effects on LDL-C (MD −0.07 mmol/L; 95% CI [−0.19, 0.05]; certainty of evidence: Low). This represents a key finding: at the population level across RCTs, seal oil's effect on LDL cholesterol is not statistically significant, and the certainty of evidence is rated as low.

For triglycerides, a direct comparative RCT published in European Journal of Clinical Nutrition (Meyer et al., 2009) examined 48 hypertriglyceridemic volunteers. Forty-eight volunteers were randomly allocated to one of three groups receiving 1 g/day of long-chain omega-3 PUFA using either seal oil capsules (340 mg EPA, 230 mg DPA, 450 mg DHA), fish oil capsules (210 mg EPA, 30 mg DPA, 810 mg DHA), or placebo capsules containing sunola oil for 6 weeks. Plasma triglycerides remained unchanged in the placebo group, whilst reductions of 7% and 14% (P < 0.05) were seen in the fish oil and seal oil groups respectively.

An earlier long-term RCT (Brox et al., 2001; PubMed 11214732) compared seal oil versus cod liver oil in hypercholesterolemic subjects. In this long-term study, 120 clinically healthy hypercholesterolemic subjects (total cholesterol 7.0–9.5 mmol/L) were randomly selected to consume either 15 mL of seal oil (SO) or cod liver oil (CLO) daily for 14 months, followed by a 4-month washout period, with a third group receiving no dietary supplement. Test parameters included fatty acid composition in serum, blood lipids, platelet aggregation, and monocyte activity.

A small preliminary study (Conquer et al., 2001; PubMed 11428220) assessed atherosclerosis risk factors. Two intervention studies were carried out in healthy volunteers: in Study I, ten volunteers added 10 capsules of seal oil to their normal Western diet for six weeks, with blood tests for total, HDL, and LDL cholesterol, plasma triglycerides, and the n-6/n-3 fatty acid ratio; in Study II, five volunteers took 5 capsules daily for six weeks, with additional assessment of TNF-alpha cytokine in lymphocytes. A slightly decreased, however not significant, effect was observed for each of the cholesterol fractions after seal oil supplementation.

Omega-3 Meta-Analysis Evidence (Broader Marine Oil Context)

The cardiovascular evidence base for marine omega-3s more broadly (from fish and marine mammal sources, including blubber oil) has been extensively reviewed. A meta-analysis of 38 randomized controlled trials noted moderate certainty of evidence favoring omega-3 FAs for reducing cardiovascular mortality and outcomes; the magnitude of relative reductions was robust in EPA trials versus those of EPA+DHA, suggesting differential effects of EPA and DHA. Evidence for primary prevention of CVD through RCTs is relatively weak; in high-risk patients, especially in the secondary prevention setting (e.g., post-MI), a number of large RCTs support the use of EPA + DHA (or EPA alone). Cardiovascular disease remains the leading cause of death worldwide; supplementation with EPA and DHA is an effective lifestyle strategy for CVD prevention, and the protective effect probably increases with dosage.

In the VITAL trial, 840 mg/d of EPA and DHA resulted in a 28% reduced risk for heart attacks, 50% reduced risk for fatal heart attacks, and 17% reduced risk for total coronary heart disease events; in the ASCEND trial, cardiovascular disease death was significantly reduced by 19% with 840 mg/d of EPA and DHA; however, the primary composite endpoints were not significantly reduced in either study. These trials used fish-oil-derived preparations; no equivalently powered trials have been conducted using seal blubber oil specifically.

Evidence Strength Summary (Cardiovascular)

The available evidence from seal-oil-specific RCTs is limited in number (9 RCTs totalling 626 participants in the most comprehensive meta-analysis to date), small in sample size, and associated with low certainty of evidence for effects on LDL-C. Triglyceride-lowering data are more consistent but derived from small trials. The broader marine-omega-3 cardiovascular evidence base is substantially larger and shows more robust effects at higher doses; however, the degree to which results from fish oil studies can be extrapolated to seal/blubber oil specifically is uncertain.

5.2 Nonalcoholic Fatty Liver Disease (NAFLD)

One of the largest single seal-oil-specific clinical trials examined the effect on NAFLD. The aim was to investigate the efficacy and safety of n-3 PUFAs from seal oils for patients with NAFLD associated with hyperlipidemia; 144 patients were included in a 24-week randomized controlled trial in which Group A (n = 72) received recommended diet and 2 g n-3 PUFA from seal oils three times a day, while Group B (n = 72) received recommended diet and 2 g placebo three times a day; primary endpoints were fatty liver symptom scores, liver ALT, and serum lipid levels at weeks 8, 12, 16, and 24. The authors concluded that n-3 PUFA from seal oils is safe and efficacious for patients with NAFLD associated with hyperlipidemia and can improve total symptom scores, ALT, serum lipid levels, and normalization of ultrasonographic evidence; however, they noted that further study is needed to confirm these results.

This trial has been cited in broader reviews of omega-3 PUFA use in NAFLD. In 144 patients with NAFLD and mixed hyperlipidemia, at the end of the treatment period (24 weeks), total symptom scores, ALT, triglyceride levels, and fatty liver scores decreased more significantly in the group treated with 2,000 mg of seal oils than in the placebo group. The interventions used in broader NAFLD omega-3 reviews have included DHA alone, combinations of EPA+DHA, or omega-3 PUFA preparations from fish or seal oil; doses ranged from 0.25 to 6.8 grams of oil/day for 3–25 months.

Evidence strength: Promising but preliminary. The positive NAFLD trial was conducted at a single center (China), and its authors explicitly called for confirmatory studies. The broader omega-3 NAFLD literature shows inconsistent findings, and large, well-powered trials specifically using seal oil are lacking.

5.3 Platelet Aggregation and Hemostasis

A study in 11 male volunteers (PubMed 21043710) measured platelet aggregation induced by microbubbles before and after intake of 15 mL seal oil (Pagophilus groenlandicus) per day. The study tested whether seal oil reduced platelet sensitivity toward microbubbles simulating those developing during deep-sea diving or extracorporeal circulation. A separate RCT (Mann et al., 2010; Lipids 45(8):669–81) directly compared seal oil and tuna-fish oil on platelet parameters and plasma lipid levels in healthy subjects. Interventional studies with seal oil supplementation (containing natural DPA in addition to EPA and DHA) indicated a significant elevation in the circulating levels of all three omega-3 fatty acids.

In the 1970s, Bang and Dyerberg demonstrated that a high intake of n-3 acids in Greenland protected against ischemic heart disease, starting the interest in fish oil as a preventive component in cardiac disease. That foundational epidemiological work was based primarily on the consumption of marine mammal and fish products, including blubber.

Evidence strength: Platelet and hemostatic effects of seal oil are supported by small, short-duration trials. Evidence is preliminary; no large RCTs are available specifically for seal oil.

5.4 Inflammation and Immune Modulation

The preliminary study by Conquer et al. (2001) included a component on inflammation: the effect on the pro-inflammatory TNF-alpha cytokine in lymphocytes was also determined in Study II. The results of this very small pilot were not statistically significant for cholesterol endpoints. The anti-inflammatory mechanisms of marine omega-3s (EPA, DHA) are well-established in the broader literature through modulation of eicosanoid pathways (reducing pro-inflammatory prostaglandins and leukotrienes) and via resolvins and protectins; these mechanisms are understood to apply to the EPA and DHA component of blubber oil, but clinical trials specifically using seal or blubber oil for inflammatory conditions are limited.

6. Body Systems and Health Areas of Association

Cardiovascular system: Health Canada's seal oil monograph cites seal oil as a source of omega-3 fatty acids for the maintenance of good health and lists claims to help support/maintain normal heart/cardiovascular health.
Lipid metabolism: Health Canada's monograph also supports the claim that seal oil helps reduce blood triglycerides/triacylglycerols.
Liver: Seal oil n-3 PUFAs have been studied in RCTs for NAFLD and hepatic steatosis, as detailed above.
Platelet and hemostatic function: Marine omega-3s in seal oil have demonstrated modulation of platelet aggregation in small human studies.
Immune and inflammatory function: Broader n-3 mechanisms include modulation of pro-inflammatory cytokines and eicosanoid pathways.
Nutritional adequacy in omega-3 deficient populations: Intake of EPA+DHA among Greenlandic Inuit was notably high due to reliance on whale, seal, and fish meat; by contrast, in the United States, Australia, Belgium, Germany, the United Kingdom, and Canada, average daily intake falls far short of the recommendation for CVD prevention (~500 mg/d EPA/DHA), with intakes approximating 100–290 mg/d or less.

7. Dosage Forms and Dosages Reported in Studies

The following dosages are drawn directly from the sources cited above and from regulatory monographs; they are not recommendations.

Health Canada Natural Health Product Monograph (Seal Oil): Products providing 100–5,000 milligrams of EPA, DHA, and DPA per day are recognized as a source of omega-3 fatty acids for the maintenance of good health.
NAFLD RCT (Zhu et al., 2008; World J Gastroenterol): Group A received 2 g n-3 PUFA from seal oils three times a day (total 6 g/day of seal oil PUFA); Group B received 2 g placebo three times a day.
Hypertriglyceridemia RCT (Meyer et al., 2009; Eur J Clin Nutr): Volunteers received 1 g/day of total long-chain n-3 PUFA from seal oil capsules containing 340 mg EPA, 230 mg DPA, and 450 mg DHA for 6 weeks.
Atherosclerosis pilot studies (Conquer et al., 2001): Study I used 10 capsules of seal oil added to the normal Western diet for 6 weeks; Study II used 5 capsules of seal oil daily for 6 weeks.
Long-term hypercholesterolemia RCT (Brox et al., 2001): 15 mL of seal oil daily for 14 months, following a 6-month run-in period.
Platelet study (Moller et al.): 15 mL seal oil (Pagophilus groenlandicus) per day as referenced in PubMed 21043710.
Dosage forms (Health Canada): Children aged 6–11 years, adolescents 12–17 years, and adults 18 years and older may use oral dosage forms including soft gelatin capsules (including enteric-coated), liquids, and emulsions.
Oxidative quality specifications (Health Canada): Peroxide, anisidine, and totox values of seal oil or omega-3 fatty acids derived from seal oil must be in accordance with AOAC or pharmacopoeial analytical methods to ensure oxidative stability; the maximum peroxide value (PV) must be 5 mEq/kg and the maximum anisidine value (AV) must be 20.

8. Safety Considerations and Known Contaminants

Persistent Organic Pollutants and Heavy Metals

As apex marine predators, seals and whales accumulate lipophilic environmental contaminants in their blubber through bioaccumulation. Polychlorinated biphenyls (PCBs), organochlorine pesticides such as DDT, and polybrominated flame retardants are apolar, lipophilic, persistent, and ubiquitous environmental pollutants; as apex predators, marine mammals are exposed to biomagnified concentrations of these POPs via their diet, accumulating highest levels in lipid-rich tissues such as blubber. Exposure to organochlorines can cause hepatic, reproductive, and immune toxic effects often involving endocrine-disrupting mechanisms.

Dioxins, polychlorinated dibenzo-para-dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs); dioxin-like PCBs; and PCBs are recognized contaminants in oils from marine sources, and testing for these contaminants is required under Health Canada's regulatory framework for natural health products. Licence holders are advised to consult the Commission of the European Communities documents on dioxins and dioxin-like PCB contaminants in marine oil.

The percent of adipose tissue has a significant relationship with inner blubber PCB concentrations, with the highest mean concentrations observed at the end of the molting fast; these results highlight the importance of sampling across the entire blubber layer when assessing contaminant levels and taking into account adipose stores and reproductive status when conducting contaminant research.

Refining and Purification

Commercial seal oil supplements undergo refining processes intended to remove environmental contaminants while preserving omega-3 content. Unsaturated fatty acids from the blubber are less peroxidized than those extracted from muscles. Quality specifications set by Health Canada require oxidative stability testing; specifically, peroxide, anisidine, and totox values of seal oil or omega-3 fatty acids derived from seal oil must be in accordance with the methods set out by AOAC and/or pharmacopoeial analytical methods.

Anticoagulant Effects

Marine omega-3 fatty acids, including those in seal oil, can reduce platelet aggregation. More than half of pharmacists surveyed expressed concerns about increased risk of hemorrhage from omega-3 supplementation; however, omega-3 fatty acids do not increase the risk of clinically significant bleeding at recommended doses. Nonetheless, the platelet-modifying effects of seal oil at higher doses, or when combined with anticoagulant or antiplatelet drugs, warrant consideration.

Oxidative Stability

No moisture and volatile matter could be detected in blubber oil; however, exposure to 125°C oxidizes blubber oil readily. Oxidative rancidity is a recognized concern for all marine oil products and is controlled through quality standards, antioxidant addition (typically vitamin E), and proper storage.

Regulatory and Legal Considerations

The regulatory status of blubber oil supplements varies substantially by jurisdiction. In Canada, seal oil holds authorized natural health product status under Health Canada's Natural Health Products Regulations, with a published monograph detailing permitted claims, dosage ranges, and quality requirements. In the European Union and the United States, the commercial sale of marine mammal-derived products (including blubber oil and seal oil) is severely restricted or prohibited under wildlife protection and import laws. A small amount of commercial whaling still occurs; however, in the twenty-first century, with most countries having banned whaling, the sale and use of whale oil has practically ceased. Inuit and other recognized indigenous communities retain cultural and subsistence harvesting rights in various jurisdictions.

References

Health Conditions

Health conditions that Blubber oil may help support.

No conditions available.

Body Systems

Body systems that Blubber oil may help support.

No body systems available.